Literature DB >> 18458136

In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

Sheng-Yuan Ruan1, Chen-Chen Chu, Po-Ren Hsueh.   

Abstract

Voriconazole, posaconazole, caspofungin, micafungin, and anidulafungin demonstrated potent in vitro activities against 286 invasive Candida isolates. Analysis of the fluconazole susceptibilities of 204 bloodstream Candida glabrata isolates revealed a rapid shift from susceptible (64% in 1999 to 2001 to 19% in 2007) to susceptible-dose dependent (27% in 1999 to 2001 and 75% in 2007).

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18458136      PMCID： PMC2493111          DOI： 10.1128/AAC.00323-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

Review 2.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

Review 3.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

4.  Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.

Authors:  A Minari; R Hachem; I Raad
Journal:  Clin Infect Dis       Date:  2000-12-28       Impact factor: 9.079

5.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

Authors:  W E Trick; S K Fridkin; J R Edwards; R A Hajjeh; R P Gaynes
Journal:  Clin Infect Dis       Date:  2002-08-02       Impact factor: 9.079

6.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 7.  Antifungal drug resistance to azoles and polyenes.

Authors:  Mar Masiá Canuto; Félix Gutiérrez Rodero
Journal:  Lancet Infect Dis       Date:  2002-09       Impact factor: 25.071

8.  Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.

Authors:  John E Bennett; Koichi Izumikawa; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.

Authors:  Elisabetta Spreghini; Carmelo Massimo Maida; Maria Eleonora Milici; Giorgio Scalise; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191
View more
  10 in total

1.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 2.  Anidulafungin, a new echinocandin: in vitro activity.

Authors:  Giulia Morace; Elisa Borghi; Roberta Iatta; Maria Teresa Montagna
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.

Authors:  Hatice Turk Dagi; Duygu Findik; Cigdem Senkeles; Ugur Arslan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-31       Impact factor: 3.944

4.  Evaluation of miR-146a expression level in macrophages exposed to Candida glabrata.

Authors:  B Arghavan; M Sharifi; M Shafiee; R Mohammadi
Journal:  Curr Med Mycol       Date:  2016-06

5.  Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

Authors:  Bertrand F Dupont; Olivier Lortholary; Luis Ostrosky-Zeichner; Flavie Stucker; Vijay Yeldandi
Journal:  Crit Care       Date:  2009-10-05       Impact factor: 9.097

6.  Antifungal activity of fused Mannich ketones triggers an oxidative stress response and is Cap1-dependent in Candida albicans.

Authors:  Tristan Rossignol; Béla Kocsis; Orsolya Bouquet; Ildikó Kustos; Ferenc Kilár; Adrien Nyul; Péter B Jakus; Kshitij Rajbhandari; László Prókai; Christophe d'Enfert; Tamás Lóránd
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

7.  Role of Dectin-2 for host defense against systemic infection with Candida glabrata.

Authors:  Daniela C Ifrim; Judith M Bain; Delyth M Reid; Marije Oosting; Ineke Verschueren; Neil A R Gow; J Han van Krieken; Gordon D Brown; Bart-Jan Kullberg; Leo A B Joosten; Jos W M van der Meer; Frank Koentgen; Lars P Erwig; Jessica Quintin; Mihai G Netea
Journal:  Infect Immun       Date:  2013-12-16       Impact factor: 3.441

8.  In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.

Authors:  Nasrin Amirrajab; Hamid Badali; Mojtaba Didehdar; Mohammad Hosein Afsarian; Rasoul Mohammadi; Nazanin Lotfi; Tahereh Shokohi
Journal:  Jundishapur J Microbiol       Date:  2016-04-23       Impact factor: 0.747

9.  Epidemiology and antifungal susceptibility of candidemia isolates of non-albicans Candida species from cancer patients.

Authors:  Ping-Feng Wu; Wei-Lun Liu; Min-Han Hsieh; Ing-Moi Hii; Yu-Lin Lee; Yi-Tsung Lin; Mao-Wang Ho; Chun-Eng Liu; Yen-Hsu Chen; Fu-Der Wang
Journal:  Emerg Microbes Infect       Date:  2017-10-11       Impact factor: 7.163

10.  Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes.

Authors:  Tobias Schwarzmüller; Biao Ma; Ekkehard Hiller; Fabian Istel; Michael Tscherner; Sascha Brunke; Lauren Ames; Arnaud Firon; Brian Green; Vitor Cabral; Marina Marcet-Houben; Ilse D Jacobsen; Jessica Quintin; Katja Seider; Ingrid Frohner; Walter Glaser; Helmut Jungwirth; Sophie Bachellier-Bassi; Murielle Chauvel; Ute Zeidler; Dominique Ferrandon; Toni Gabaldón; Bernhard Hube; Christophe d'Enfert; Steffen Rupp; Brendan Cormack; Ken Haynes; Karl Kuchler
Journal:  PLoS Pathog       Date:  2014-06-19       Impact factor: 6.823
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.